Bristol-Myers Squibb Sustainability Profile
Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading global biopharmaceutical firm headquartered in the United States. Founded in 1887, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative medicines in oncology, immunology, and cardiovascular disease. BMS is renowned for its groundbreaking therapies, such as Opdivo and Eliquis, which have transformed treatment paradigms and improved patient outcomes. The company’s commitment to research and development has positioned it as a key player in the pharmaceutical industry, consistently achieving significant milestones, including numerous FDA approvals and recognitions for its contributions to healthcare. With a robust pipeline and a dedication to addressing unmet medical needs, Bristol-Myers Squibb continues to solidify its market position as a pioneer in biopharmaceutical innovation.
DitchCarbon Score
How does Bristol-Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bristol-Myers Squibb's score of 75 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bristol-Myers Squibb's reported carbon emissions
In 2023, Bristol-Myers Squibb (BMS) reported total greenhouse gas emissions of approximately 2,117,929,000 kg CO2e globally. This includes 208,535,000 kg CO2e from Scope 1 (direct emissions) and 158,447,000 kg CO2e from Scope 2 (indirect emissions). Notably, BMS has not disclosed any Scope 3 emissions data for this year. BMS has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across all scopes by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 54.6% by 2033, using 2022 as the base year. Additionally, BMS plans to reduce Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. By 2028, BMS aims for 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets. Long-term, BMS commits to a 90% reduction in absolute Scope 1, 2, and 3 emissions by 2050, again using 2022 as the baseline year. These targets align with the Science Based Targets initiative (SBTi) and reflect BMS's commitment to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Bristol-Myers Squibb's Industry?
How Carbon Intensive is Bristol-Myers Squibb's Location?
Bristol-Myers Squibb's Scope 3 Categories Breakdown
Bristol-Myers Squibb's Scope 3 emissions, which decreased by 1% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
Bristol-Myers Squibb's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bristol-Myers Squibb has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Thermo Fisher Scientific
Frequently Asked Questions
Common questions about Bristol-Myers Squibb's sustainability data and climate commitments